Jazz Pharmaceuticals (JAZZ) Total Non-Current Liabilities (2011 - 2026)

Jazz Pharmaceuticals has reported Total Non-Current Liabilities for 16 years, with the latest figure at $7.2 billion in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities fell 1.42% year-over-year to $7.2 billion; the trailing twelve-month figure through Mar 2026 stood at $7.2 billion (down 1.42% YoY), and the FY2025 full-year result was $7.2 billion, down 7.86% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $7.2 billion, down from $7.2 billion in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $8.0 billion in Q1 2022, with the low at $7.1 billion in Q2 2025.
• Average Total Non-Current Liabilities over 5 years is $7.5 billion, with a median of $7.5 billion recorded in 2023.
• Peak annual rise in Total Non-Current Liabilities reached 181.67% in 2022, while the deepest fall reached 12.06% in 2022.
• Tracing JAZZ's Total Non-Current Liabilities over 5 years: stood at $7.6 billion in 2022, then declined by 0.95% to $7.5 billion in 2023, then grew by 3.96% to $7.8 billion in 2024, then retreated by 7.86% to $7.2 billion in 2025, then dropped by 0.7% to $7.2 billion in 2026.
• The last three Total Non-Current Liabilities figures came in at $7.2 billion (Q1 2026), $7.2 billion (Q4 2025), and $7.3 billion (Q3 2025), per Business Quant data.

Peer Comparison